Alkermes' Alixorexton and Takeda's Oveporexton are leading a revolution in narcolepsy treatment, with promising results in Phase 2 and 3 trials. These OX2R receptor agonists offer hope for patients with narcolepsy type 1, improving wakefulness and reducing cataplexy.